A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
At Elutia, our mission is to humanize medicine so that patients can thrive without compromise. As a commercial-stage company, we seek to leverage our unique understanding of biologics combined with local drug delivery to improve the interaction between implanted medical devices and patients by reducing complications associated with these surgeries. These complications include infection, device migration, erosion, implant rejection, non-union of implants, fibrosis and scar formation. We estimate that more than 700,000 surgical procedures were performed annually in the United States involving the implantation of medical devices such as pacemakers, defibrillators, neurostimulators or tissue expanders for breast reconstruction.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 14M | - | 25M | 24M | 47M | 43M |
| Net Income | -26M | -54M | -38M | -33M | -25M | -25M |
| EPS | $-0.87 | $-1.86 | $-2.07 | $-2.38 | $-2.38 | $-8.88 |
| Free Cash Flow | -33M | -23M | -22M | -22M | -16M | -14M |
| ROIC | -77.3% | -78.0% | -55.5% | -1242.1% | -1139.3% | -65.6% |
| Gross Margin | 48.4% | - | 44.7% | 48.8% | 40.1% | 48.2% |
| Debt/Equity | 0.00 | -0.49 | -0.53 | -4.82 | 1.37 | 1.16 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -29M | -36M | -31M | -35M | -23M | -14M |
| Operating Margin | -198.6% | - | -123.4% | -147.5% | -48.6% | -31.9% |
| ROE | 0.0% | - | - | - | -183.7% | -121.6% |
| Shares Outstanding | 40M | 29M | 18M | 14M | 10M | 14M |
| Metric | 2019 | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 43M | 43M | 47M | 24M | 25M | N/A | 14M |
| Gross Margin | 46.1% | 48.2% | 40.1% | 48.8% | 44.7% | N/A | 48.4% |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -8.4M | -14M | -23M | -35M | -31M | -36M | -29M |
| Op. Margin | -19.6% | -31.9% | -48.6% | -147.5% | -123.4% | N/A | -198.6% |
| Net Income | N/A | -25M | -25M | -33M | -38M | -54M | -26M |
| Net Margin | N/A | -59.4% | -52.4% | -137.9% | -152.2% | N/A | -182.7% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | N/A | -65.6% | N/M | N/M | -55.5% | -78.0% | -77.3% |
| ROE | N/A | -121.6% | -183.7% | N/A | N/A | N/A | 0.0% |
| ROA | N/A | -30.6% | -37.0% | -47.8% | -86.7% | -135.6% | -90.0% |
| Cash Flow | |||||||
| Op. Cash Flow | -7.2M | -14M | -15M | -21M | -22M | -23M | -32M |
| Free Cash Flow | -7.8M | -14M | -16M | -22M | -22M | -23M | -33M |
| Owner Earnings | -11M | -18M | -23M | -29M | -28M | -34M | -44M |
| CapEx | 577K | 640K | 369K | 540K | 346K | 654K | 1.1M |
| Maint. CapEx | 3.9M | 3.9M | 3.7M | 3.7M | 3.7M | 3.5M | 3.5M |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 3.9M | 3.9M | 3.7M | 3.7M | 3.7M | 3.5M | 3.5M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 208K | 779K | 3.5M | 3.6M | 2.4M | 7.9M | 7.9M |
| Debt Repayment | 112K | 300K | 2.8M | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | 19M | -15M | -12M | 7.3M | 4.4M | 11M | 21M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | 4.7M |
| Long-Term Debt | 20M | 18M | 10M | 24M | 20M | 23M | 23M |
| Debt/Equity | -0.36 | 1.16 | 1.37 | -4.82 | -0.53 | -0.49 | 0.00 |
| Interest Coverage | -1.6 | -2.4 | -4.3 | -6.9 | -5.3 | -7.5 | -7.5 |
| Equity | -55M | 21M | 14M | -5.0M | -39M | -46M | -44M |
| Total Assets | 45M | 83M | 67M | 69M | 43M | 36M | 29M |
| Total Liabilities | 100M | 62M | 54M | 74M | 82M | 82M | 73M |
| Intangibles | N/A | 44M | 37M | 30M | 23M | 17M | 17M |
| Retained Earnings | -57M | -80M | -105M | -138M | -176M | -230M | -230M |
| Working Capital | 172K | 33M | 21M | 8.1M | -12M | -12M | -12M |
| Current Assets | 18M | 60M | 47M | 51M | 31M | 26M | 26M |
| Current Liabilities | 18M | 27M | 26M | 43M | 43M | 38M | 38M |
| Per Share Data | |||||||
| EPS | -18.48 | -8.88 | -2.38 | -2.38 | -2.07 | -1.86 | -0.87 |
| Owner EPS | -1.10 | -1.35 | -2.18 | -2.08 | -1.54 | -1.17 | -1.08 |
| Book Value | -5.39 | 1.54 | 1.30 | -0.36 | -2.12 | -1.59 | -1.09 |
| Cash Flow/Share | -0.71 | -1.00 | -1.48 | -1.55 | -1.20 | -0.78 | -0.57 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 10.2M | 13.6M | 10.4M | 13.8M | 18.2M | 29.0M | 40.3M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -1.3 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 8.4 | 4.2 | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | 4.0 | 2.2 | 3.7 | 1.7 | N/A | 3.2 |
| FCF Yield | N/A | -8.2% | -27.7% | -39.8% | -57.3% | -20.4% | -72.5% |
| Market Cap | N/A | 174M | 57M | 55M | 39M | 114M | 46M |
| Avg. Price | N/A | 12.47 | 10.16 | 6.35 | 2.35 | 3.62 | 1.14 |
| Year-End Price | N/A | 12.84 | 5.47 | 3.99 | 2.12 | 3.94 | 1.14 |
ELUTIA INC. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 45.4%. At current prices, the estimated annualized return to fair value is +5.1%.
ELUTIA INC. (ELUT) has a 5-year average return on invested capital (ROIC) of -66.4%. This is below average and may indicate limited pricing power.
ELUTIA INC. (ELUT) has a market capitalization of $46M. It is classified as a small-cap stock.
ELUTIA INC. (ELUT) does not currently pay a regular dividend.
ELUTIA INC. (ELUT) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
ELUTIA INC. (ELUT) generated $-23 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ELUTIA INC. (ELUT) reported earnings per share (EPS) of $-1.86 in its most recent fiscal year.
ELUTIA INC. (ELUT) has a 5-year average gross margin of 45.4%. This indicates decent pricing power.
The Ledger Terminal provides 6 years of financial data for ELUTIA INC. (ELUT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ELUTIA INC. (ELUT) has a book value per share of $-1.59, based on its most recent annual SEC filing.